In 1992, Orchid obtained a certificate for commencement of business and became a public company the following year. It began producing commercially in 1995 and received the Good manufacturing practice certification.
In 1999, it became the largest producer of oral and sterile cephalosporin and was ranked among the top five producers of cephalosporin APIs. That same year, the formulation division began operations. The early 2000s, the company established offices in the United States and Russia, then signed an agreement to produce oral cephalosporin for the U.S. market in the mid-2000s.
The company had a joint venture with Bexel allowing it to complete its phase 1(a), (b) and phase 2(a) clinical trails for the anti-diabetic molecule BLX-1002 and get patent clearance in the U.S.. After obtaining the patent, the company made an agreement with pharmaceutical companies in Canada to help produce oral drugs and veterinarian injectables before expanding its market into Europe. In 2008 and 2009, the company received approval to enter the Canadian and Australian markets and established a wholly owned subsidiary in Japan.
Contact Details:-
Orchid Chemicals & Pharmaceuticals Ltd.
'Orchid Towers'
313, Valluvar Kottam High Road
Nungambakkam
Chennai - 600 034
Tamil Nadu,
313, Valluvar Kottam High Road
Nungambakkam
Chennai - 600 034
Tamil Nadu,
India
Phone: +91 - 44 - 2821 1000 / 2823 0000
Fax: +91 - 44 - 2821 1002
E-mail: corporate@orchidpharma.com
Phone: +91 - 44 - 2821 1000 / 2823 0000
Fax: +91 - 44 - 2821 1002
E-mail: corporate@orchidpharma.com
Also check:-
Rate this posting:
{[['
']]}
']]}
0 comments :
Post a Comment